Concord Drugs (BOM:538965) PEG Ratio: N/A (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:538965 Concord Drugs Ltd BOM:538965
67 GF Score
Price ₹71.23
GF Value ₹60.93
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Concord Drugs PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Concord Drugs's PE Ratio without NRI is 75.78. Concord Drugs's 5-Year EBITDA growth rate is -13.00%. Therefore, Concord Drugs's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Concord Drugs's PEG Ratio or its related term are showing as below:


During the past 13 years, Concord Drugs's highest PEG Ratio was 1943.50. The lowest was 2.83. And the median was 6.32.


BOM:538965's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.75
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Concord Drugs  (BOM:538965) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Concord Drugs PEG Ratio Related Terms


Concord Drugs PEG Ratio Historical Data

* Premium members only.

The historical data trend for Concord Drugs's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Drugs PEG Ratio Chart

Concord Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.17 8.33 24.62 0.00 0.00

Concord Drugs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BOM:538965 vs ZTS: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Drugs PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Concord Drugs's PEG Ratio falls into.


BOM:538965
67GF Score
Concord Drugs Ltd BOM:538965
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Drugs PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Concord Drugs's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=75.776595744681/-13.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Concord Drugs (BOM:538965) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued. The current stock price of ₹71.23 is trading 16.9% above its estimated GF Value™ of ₹60.93. GuruFocus considers Concord Drugs to be Modestly Overvalued.

Key valuation signals for BOM:538965:

  • PEG Ratio: N/A
  • GF Value™: ₹60.93 vs. price of ₹71.23 (16.9% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Concord Drugs Business Description

Address Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
67GF Score

Get the complete analysis for BOM:538965

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹71.23
Price
₹60.93
GF Value